Solution-Mediated Polymorphic Transformation from Risperidone Form II to Form I

[1]  Tao Li,et al.  Exploring the solvent effect on risperidone (form I) crystal morphology: a combination of molecular dynamics simulation and experimental study , 2023, Journal of Molecular Liquids.

[2]  Q. Yin,et al.  Analysis of Solid-liquid Equilibrium Behavior of Highly Water-Soluble Beet Herbicide Metamitron in Thirteen Pure Solvents Using Experiments and Molecular Simulations , 2022, Journal of Molecular Liquids.

[3]  Guimin Zhang,et al.  Nucleation behavior of isosorbide 5-mononitrate revealed from metastable zone widths by combining nucleation theory model and molecular simulation , 2022, Journal of Molecular Liquids.

[4]  Tao Li,et al.  Thermodynamic analysis and molecular dynamic simulation of the solubility of risperidone (form I) in the pure and binary solvents , 2022, Journal of Molecular Liquids.

[5]  H. Hao,et al.  Selective Nucleation of Polymorphs Induced by Multiple Conformations and Self-Association , 2022, Crystal Growth & Design.

[6]  Yuanfeng Wei,et al.  Thermodynamic and Kinetic Studies on the Polymorphic Transformations of Puerarin Hydrates. , 2021, International journal of pharmaceutics.

[7]  Q. Yin,et al.  The effect of solvents on crystal morphology of sucralose: Experiments and molecular dynamics simulation studies , 2020 .

[8]  Hongyuan Wei,et al.  Solution-mediated polymorphic transformation of CL-20: An approach to prepare purified form ε particles , 2018, Journal of Molecular Liquids.

[9]  E. Spina,et al.  A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone , 2017, Expert review of clinical pharmacology.

[10]  J. Chen,et al.  Investigation of a solution‐mediated phase transformation of pranlukast DMF solvate to hemihydrate , 2017 .

[11]  Xijian Liu,et al.  Crystal characterization and transformation of the forms I and II of anticoagulant drug rivaroxaban , 2017 .

[12]  Hongyuan Wei,et al.  Insights into Cocrystal Polymorphic Transformation Mechanism of Ethenzamide–Saccharin: A Combined Experimental and Simulative Study , 2016 .

[13]  Å. Rasmuson,et al.  Influence of solvent on crystal nucleation of risperidone. , 2015, Faraday discussions.

[14]  Åke C. Rasmuson,et al.  Solution-Mediated Polymorphic Transformation of FV Sulphathiazole , 2014 .

[15]  H. Hao,et al.  Solution-Mediated Polymorphic Transformation of Prasugrel Hydrochloride from Form II to Form I , 2014 .

[16]  W. Dong,et al.  Solution‐Mediated Phase Transformation of a Hydrate to its Anhydrous Form of Donepezil Hydrochloride , 2013 .

[17]  B. K. Hodnett,et al.  Investigation into the mechanism of solution-mediated transformation from FI to FIII carbamazepine : The role of dissolution and the interaction between polymorph surfaces , 2013 .

[18]  B. K. Hodnett,et al.  Solution Mediated Polymorphic Transformation: Form II to Form III Piracetam in Ethanol , 2012 .

[19]  B. K. Hodnett,et al.  Examining Solution and Solid State Composition for the Solution-Mediated Polymorphic Transformation of Carbamazepine and Piracetam , 2012 .

[20]  M. Khan,et al.  Risperidone solid dispersion for orally disintegrating tablet: its formulation design and non-destructive methods of evaluation. , 2010, International journal of pharmaceutics.

[21]  Bernard Van Eerdenbrugh,et al.  Crystallization tendency of active pharmaceutical ingredients following rapid solvent evaporation--classification and comparison with crystallization tendency from undercooled melts. , 2010, Journal of pharmaceutical sciences.

[22]  Marco Mazzotti,et al.  Experimental Characterization and Population Balance Modeling of the Polymorph Transformation of l-Glutamic Acid , 2009 .

[23]  E. Martin,et al.  An Examination of the Kinetics of the Solution-Mediated Polymorphic Phase Transformation between α- and β-Forms of l-Glutamic Acid as Determined Using Online Powder X-ray Diffraction† , 2008 .

[24]  Xiurong Hu,et al.  Crystalline form B of risperidone , 2006 .

[25]  J. Ulrich,et al.  Pseudopolymorphs in Industrial Use , 2001 .

[26]  D. Grant,et al.  Polymorph screening: influence of solvents on the rate of solvent-mediated polymorphic transformation. , 2001, Journal of pharmaceutical sciences.

[27]  S. Itai,et al.  Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. , 2000, International journal of pharmaceutics.

[28]  H. Brittain.  Polymorphism in Pharmaceutical Solids , 1999 .

[29]  H. Sun,et al.  COMPASS: An ab Initio Force-Field Optimized for Condensed-Phase ApplicationsOverview with Details on Alkane and Benzene Compounds , 1998 .

[30]  J. D. den Boer.  Risperidone in the treatment of psychosis; a concise review , 1995, Acta Neuropsychiatrica.

[31]  N. Blaton,et al.  Structure of 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (risperidone) , 1993 .

[32]  B. D. Sharma.  Allotropes and polymorphs , 1987 .

[33]  W. Fan.  Investigation on crystal structure and thermal stability of risperidone , 2014 .

[34]  W Press,et al.  Crystalline solids. , 1980, Science.

[35]  D. Fox.  Physics and Chemistry of the Organic Solid State , 1963 .